The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.
Drug Advisory Committee February 2026 Meeting Outcome
Generic / Brand name
Meeting outcome
Primary reason for unsuccessful application1
1
Amivantamab (Rybrevant)
Unsuccessful
The justification of the treatment’s cost in relation to its benefits is insufficient
2
Belimumab (Benlysta)
Approved
3
Bempedoic acid (Nilemdo)
Approved
4
Bimekizumab (Bimzelx)
Pending
Pending further information
5
Brentuximab Vedotin (Adcetris)
Approved
6
Capivasertib (Truqap)
Unsuccessful
The justification of the treatment’s cost in relation to its benefits is insufficient
7
Elacestrant (Orserdu)
Unsuccessful
The justification of the treatment’s cost in relation to its benefits is insufficient
8
Empagliflozin (Jardiance)
Unsuccessful
Alternative(s) available in HADF with comparable benefits
9
Luspatercept (Reblozyl)
Approved
10
Marstacimab (Hympavzi)
Unsuccessful
The justification of the treatment’s cost in relation to its benefits is insufficient
11
Methoxyflurane (Penthrox)
Unsuccessful
Alternative(s) available in HADF with comparable benefits
12
Nintedanib (Ofev)
Approved
13
Pertuzumab / Trastuzumab (Phesgo)
Approved
14
Ranibizumab (Lucentis)
Approved
15
Repotrectinib (Augtyro)
Unsuccessful
The justification of the treatment’s cost in relation to its benefits is insufficient
16
Ruxolitinib (Jakavi)
Approved
17
Selpercatinib (Retsevmo)
Approved
18
Tislelizumab (Tevimbra)
Unsuccessful
Insufficient evidence to demonstrate significant clinical outcome benefits
19
Vutrisiran (Amvuttra)
Unsuccessful
The justification of the treatment’s cost in relation to its benefits is insufficient
1The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.
DAC Meeting Outcome
